Market Research Report
Global CAR-T Cell Therapy Market - 2019-2026
|Published by||DataM Intelligence||Product code||859738|
Delivery time: 1-2 business days
|Global CAR-T Cell Therapy Market - 2019-2026|
|Published: February 2, 2020||Content info:||
CAR-T Cell Therapy Market
The Global CAR-T Cell Therapy market was valued at USD XX million in 2018 and expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.
Chimeric antigen receptor T-cell therapy, also called CAR-T therapy, is the type of treatment in which a patient's T cells have been genetically engineered to produce chimeric antigen receptor (CAR) T-cells which are used to recognize cancer cells to more effectively target and destroy them. CARs are proteins that allow the T cells to recognize an antigen on specific tumor cells. CAR-T cells may remain in the body months after the infusion has been completed and help cancer cells from returning. CAR-T cell therapy is an incredibly promising emerging treatment for cancer patients and is increasingly being preferred over chemotherapy, surgery, and radiation.
Global CAR-T Cell Therapy Market - Market Dynamics
The global market for the CAR-T Cell Therapy Market is primarily driven by the growing prevalence of cancer coupled with high demand for an effective treatment for cancer. According to the World Health Organization, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in five men and one in six women worldwide develop cancer during their lifetime. Moreover, technological advancements for the reliable treatment of cancer, increasing investments in R&D by crucial market players, governmental initiatives on treatment and research and the growing number of people with immune to chemotherapy and radiations are expected to boost the market growth. For instance, in May 2019, Ziopharm Oncology Inc., a clinical stage immuno-oncology company developing next-generation cell and gene therapies, signed an exclusive licensing agreement with the National Cancer Institute (NCI) for intellectual property for the development and commercialization of cell therapies for cancer with the Company's Sleeping Beauty platform. In April 2019, Allogene Therapeutics Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, published preclinical study results of ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), as a potential novel treatment for multiple myeloma and other BCMA-positive malignancies, in Molecular Therapy.
However, the stringent regulations, side effects leading to neurological problems coupled with the high cost of treatment may hinder market progress.
Global CAR-T Cell Therapy Market - Segment Analysis
By Target Antigen, the global CAR-T Cell therapy market is segmented into CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRV III, and others. CD 19 antigens hold a significant market share as they are the most common target have shown remarkable success in a range of blood cancers and already have two approved therapies, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), in the market unlike some of the other target antigens that are still in the preclinical trial phase. Moreover, the growing prevalence of acute lymphoblastic leukemia in children and adults has strengthened the dominance of CD 19 antigens to be utilized for cancer therapy. According to the National Cancer Institute, in 2016, an estimated 95,764 people were living with acute lymphocytic leukemia (ALL) in the US. The American Cancer Society's estimates there will be approximately 5,930 new cases of ALL (3,280 in males and 2,650 in females) and around 1,500 deaths from ALL (850 in males and 650 in females) in the US in 2019.
Global CAR-T Cell Therapy Market- Geographical Analysis
North America accounts for the largest share in the global CAR-T Cell Therapy market. This can be mainly attributed to factors such as rising incidents of cancer in the region, and the increasing awareness among the public regarding treatment options. According to the estimates by the American Cancer Society, in 2018, there were 1,735,350 new cancer cases diagnosed and 609,640 cancer deaths, and in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the United States. Moreover, the advanced regional healthcare infrastructure, high accessibility to advanced therapies, rise in healthcare expenditure, presence of established market players and high investment in R&D activities by them are likely to boost the North America CAR-T Cell Therapy market growth. Other factors such as increasing government initiatives favorable reimbursement policies on CAR-T Cell Therapy and exclusive availability of the two approved products, Yescarta (Gilead Sciences, Inc.) and Kymriah (Novartis AG), is further fueling market growth. For instance, in February 2019, The Centers for Medicare & Medicaid Services (CMS) proposed nationwide Medicare coverage for CAR T-cell therapies approved by the FDA under 'Coverage with Evidence Development'.
Global CAR-T Cell Therapy Market- Competitive Analysis
To increase user base and improve their CAR-T Cell Therapy market presence, companies are increasingly launching innovative products, growing FDA approvals, and have a strong pipeline. Several companies have adopted merger and acquisitions policies, geographic expansion, and collaborations to help them to stand out as strong competitors in the market and also expand its sales in the global CAR-T Cell Therapy market.
Major Players in the global CAR-T Cell Therapy market include Novartis International AG, Bluebird Bio, Celgene Corporation and Gilead Sciences.
In May 2019, Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, announced the United States Food and Drug Administration (FDA) granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma. P-BCMA-101 is an autologous CAR-T therapy developed using Poseida's piggybac platform technology. The phase II trial of P-BCMA-101 is expected to begin in the second quarter of 2019 with a potential biologics license application filing by the end of 2020.
In May 2019, AveXis, a Novartis company, announced the US FDA approved Zolgensma (onasemnogene abeparvovec-xioi),the first gene therapy for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
In February 2019, the UK biotech Cell Medica received a €7.6M ($8.7M) grant from the Cancer Prevention and Research Institute of Texas to advance an off-the-shelf CAR-T cell therapy that can work not only in blood cancer but also in solid tumors.
In January 2018, Celgene Corporation and Juno Therapeutics Inc. signed a definitive merger agreement in which Celgene has agreed to acquire Juno approximately US$9 billion.
In January 2018, Kite, a Gilead Company, entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta (axicabtagene ciloleucel) and Pfizer's utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in patients with refractory large B-cell lymphoma.